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Abstract
Background: Sleep related breathing disorders (SRBD) are associated with increased morbidity and mortality and
weight loss is recommended to overweight or obese patients with SRBD. However, maintenance of weight loss is
difficult to achieve and strategies for weight loss maintenance is needed. Orlistat is a pharmacological agent that
reduces the intestinal absorption of fat and may favour long-term weight maintenance.
Objective: To examine the change in body weight and dietary intake during a 1-year treatment with orlistat after
an initial weight loss in obese subjects with SRBD. Furthermore, to explore the dietary determinants of weight
maintenance during treatment with orlistat.
Methods: Men and women with SRBD aged 32-62 years (n = 63) participated in a 3-month dietary intervention to
increase intake of vegetables and fruit. After an initial weight loss of 3.4 kg they achieved a mean body mass index of
34.3 ± 4.7 kg/m2. Subsequently they were treated with orlistat for 1 year. During this year, dietary and behavioural
interventions to attain weight loss were provided in the course of 14 group sessions. Dietary intake, energy density
and food choices were assessed with a food frequency questionnaire before and after orlistat treatment.
Results: With orlistat, body weight decreased by a mean of 3.5 kg (95% CI 1.5, 5.5). The dietary E% from saturated
fat, intake of fatty dairy products and energy density increased after 1 year while intakes of oils, fish and vegetables
decreased (all P < 0.05). After multivariate adjustments, weight loss was associated with E% protein (R2adj = 0.19
[95% CI 0.10, 0.46]), and inversely associated with E% saturated fat (R2adj = 0.20 [95% CI 0.12, 0.47]) and fatty dairy
products (R2adj = 0.23 [95% CI 0.12, 0.49]).
Conclusions: Orlistat induced further weight loss, but dietary compliance declined with time. Increasing dietary
protein and restricting saturated fat and fatty dairy products may facilitate weight loss with orlistat.
Background
Sleep related breathing disorders (SRBD), a condition
characterized by repeated episodes of apnoea and hypo-
apnoea during sleep, is associated with increased mor-
bidity and mortality [1]. T h ep r e v a l e n c eo fS R B D
increases with increasing body mass index (BMI) and
weight loss is universally recommended to overweight
or obese patients with SRBD [2]. Recently, randomized,
long-term intervention studies have shown clinical rele-
vant improvements in the apnoea and hypo-apnoea
index with weight loss of about 10 kg [3,4].
In most weight loss programs an increased intake of
vegetables and fruit is recommended in energy reduced
diets. Vegetables and fruit have relatively high water
content that adds weight but not energy to the diet and
these food items decrease the energy density of the diet.
Indeed, dietary advice to decrease the energy density of
the diet has been suggested as a strategy for reducing
energy intake and body weight [5]. The energy density
of the diet is also influenced by the intake of fat because
fat has a higher energy density (38 kJ/g) than carbohy-
drate or protein (17 kJ/g) [6,7]. Thus, fat-restricted diets
would decrease energy density.
Orlistat is a pancreatic lipase inhibitor that reduces
the intestinal absorption of fat [8]. Gastrointestinal
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and flatulence may occur if the dietary intake of fat is
higher than recommended. Thus, orlistat may have a
policing effect on the intake of fatty foods. However,
randomized clinical trials have shown that the intake
of fat in subjects taking orlistat or placebo does not
differ substantially [9,10]. An increased intake of fat dur-
ing long-term treatment with orlistat has also been
shown [11].
We previously reported the results of a 3-month
group-based dietary and behavioural program in subjects
with SRBD [12]. The intervention group doubled the
intake of vegetables and fruit, reduced energy from total
fat and saturated fat and reduced dietary energy density.
Following the trial, subjects were offered continued diet-
ary and behavioural counselling and orlistat treatment
for 1 year. In this study we examined dietary intake,
energy density, food choices and dietary determinants of
weight change during 1 year of orlistat treatment in
obese subjects with SRBD. To our knowledge, the
impact of orlistat on energy density of the diet has not
been studied previously.
Materials and methods
Subjects
The subjects were referred from the Ear, Nose and
Throat Department or primary care physicians to Pre-
ventive Cardiology at the Oslo University Hospital for
weight reduction. The diagnosis of SRBD was verified
during polysomnography in a sleep laboratory mostly
done at the hospital. In brief, inclusion criteria were
men and women with SRBD aged 21 to 72 years with a
BMI ≥ 27 kg/m2. Exclusion criteria were drug or alco-
hol abuse or lack of motivation, major non-cardiac dis-
ease expected to reduce life expectancy or interfere with
the study and the use of appetite suppressants or weight
reducing medication within the last 3 months. The Ethi-
cal Committee (region 1) in Norway approved the pro-
tocol and all participants provided written informed
consent.
Study design
Immediately after completing the 3-month weight loss
program [12] participants in the intervention group
(n = 63) were offered orlistat free of charge in addition to
continued dietary and behavioural counselling. The parti-
cipants were instructed to take orlistat capsules (120 mg)
3 times daily at each main meal. At monthly visits body
weight and waist circumference were measured, adverse
events were reported and orlistat capsules were delivered.
Behavioural treatment consisted of 14 group sessions
lasting 90 minutes and scheduled at monthly intervals
except for the first four sessions that were scheduled
every second week. Subjects were asked to follow a diet
consisting of < 30% of energy from total fat and < 10% of
energy from saturated fat. They were asked to consume
low fat dairy products and lean meat or chicken instead
of minced meat and sausages, and to reduce intake of
cakes, biscuits, ice cream, chocolate and snacks. To
increase the palatability of the diet, a small amount of
unsaturated fat from fatty fish and plant sources was
recommended. Food exhibits demonstrated the amount
of fat in various foods. Subjects were taught to read food
labels and focus on the fat content. They were instructed
in planning for social eating and eating at restaurants.
They were given homework to assess their eating beha-
viour and to plan specific strategies to avoid pitfalls. The
behavioural program emphasized goal setting, stimulus
control and cognitive restructuring [13].
Dietary assessments
A registered dietician (MS) conducted a dietary interview
based on a food frequency questionnaire (FFQ) before
and after 1 year of treatment with orlistat. The FFQ was
designed to assess dietary intake during the last 3 months
and has been described in detail elsewhere [14]. In short,
the questionnaire elicited frequencies and consumption
of 174 food items. Portion sizes were estimated with the
use of a photographic atlas, photographs of food items
and standardized measurement units. The FFQ was
coded manually for the calculation of total energy, energy
density, energy, nutrients and food items using a software
program (Mat på data 3.0, 1996) based on the Norwegian
food composition table [15]. Energy density was calcu-
lated for the entire diet minus drinks (coffee, tea, milk,
juice, soft drinks and alcoholic beverages).
Anthropometry
Subjects were weighed (in underwear) with a digital
weight (Seca, Germany) to the nearest 0.1 kg before
start of treatment with orlistat and after 1 year. Height
was measured with a standardized wall measuring stick
scale to the nearest 0.5 cm. Waist circumference was
measured at the umbilicus with the subject unclothed
and in the standing position.
Statistical analysis
Subjects were divided into attendance groups. The sub-
jects in the high attendance group attended more group
sessions than the mean which was 9.34 sessions and the
subjects in the low attendance group attended ≤ 9.34
sessions. For the high attendance group the attendance
rate was > 66.7% and for the low attendance group the
attendance rate was ≤ 66.7%.
The results are presented as means (SD or 95% confi-
dence intervals CI) or median and 25th, 75th percentiles
as appropriate. Mean differences within and between
groups were tested with paired and unpaired t-tests,
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groups were tested with the Mann-Whitney two-sample
rank test. Pearson or Spearman correlations were used
for normally distributed or skewed variables, respec-
tively, to explore the associations between single, contin-
uous variables. Multiple regression analyses were
conducted to identify adjusted associations between
dietary variables and weight loss during treatment with
orlistat. The tests were considered statistically significant
at P < 0.05. Analyses were performed using the
Stat View 5.0.1 software (Abacus concepts, Berkeley,
California, USA).
Results
The 48 men and 15 women in the study were between
32 and 62 years of age and had a mean BMI of 34.6 ±
4.7 kg/m2. Five men did not attend the behavioural ses-
sions and are not included in the analyses. Their base-
line characteristics (age, anthropometric measurements,
established cardiovascular disease or diabetes mellitus,
pharmacological therapy and treatment with CPAP) did
not differ from men that followed the group sessions
(data not shown).
Change in dietary intake
Table 1 shows the dietary intake data at 1 year and
changes from the start of orlistat. Reported energy den-
sity and energy percent (E%) from saturated fat was
increased and E% from monounsaturated fat, carbohy-
drate and grams of fibre was reduced. Energy density
increased more in the low attendance group than in the
high attendance group. Intakes of fatty dairy products
(butter, cream and fatty cheeses) were increased and the
intake of oil, fish and vegetables were decreased in the
groups as a whole (Table 2).
Change in anthropometrics
Before orlistat was started the mean BMI was 34.3 ± 4.5
kg/m2 (range 25.9-45.6 kg/m2), and a mean waist cir-
cumference of 113.3 ± 13.8 cm (range 86-142 cm). After
1 year the mean weight reduction was -3.5 ± 8.1 kg [95%
CI -1.5, -5.5 kg]. The high attendance group achieved
better weight reduction than the low attendance group
(mean, -6.2 ± 6.6 kg] versus -0.9 ± 8.7 kg, P = 0.008).
Likewise, the high attendance group reduced waist cir-
cumference more than the low attendance group (mean,
-4.4 ± 6.3 cm versus -1.9 ± 7.3 cm, P = 0.001). Change in
weight was inversely correlated to attendance rate (r =
-0.34, [95% CI -0.10, -0.55], P = 0.056).
Change in dietary intake as predictors for weight loss
Table 3 shows the multiple regression analyses of
change in E% of protein, E% of saturated fat and fatty
d a i r yp r o d u c t sa sp r e d i c t o r sf o rw e i g h tl o s sa f t e r
adjustments for intake at baseline, attendance rate, age,
gender and BMI at baseline. After adjustments, change
in E% of protein (R2adj = 0.19 [95% CI 0.01, 0.46]), E%
of saturated fat (R2adj = 0.20 [95% CI 0.12, 0.47] and
intake of fatty dairy products (R2adj = 0.23 [95% CI 0.12,
0.49]) predicted weight loss. Changes in energy density,
E% monounsaturated fat, carbohydrates, fibre, vegeta-
bles, fish and oil were not associated with change in
weight (all P values >0.1).
Discussion
This was a study of a 1-year group-based dietary/beha-
vioural program combined with orlistat following 3
months of dietary counselling in patients with SRBD.
Our main findings were that the program was associated
with reduced body weight, but compliance to dietary
recommendations deteriorated somewhat during treat-
ment. Dietary energy density, E% from saturated fat and
intakes of fatty dairy products increased during the
1-year period. In the multiple regression analyses, further
loss of body weight was associated with increased intake
of protein and lower E% saturated fat and fatty dairy pro-
duct intakes. These variables explained almost 20% of the
variation in weight reduction. The strengths of our study
are that we have follow-up data on all subjects included
in the dietary/behavioural program and comprehensive
dietary data. A limitation is the lack of a control group
however the study was designed to demonstrate the
results of treatment in a usual clinical setting.
Despite behavioural and pharmacological support,
compliance with the diet worsened in all subjects during
the year of treatment. Deterioration of dietary compli-
ance after an initial intervention during long-time fol-
low-up is common [16]. Our data suggest that even
treatment with a pharmacolo g i c a la i da so r l i s t a ta n d
moderately intense behavioural support does not pre-
vent this deterioration. However we did observe that the
group with high attendance showed better dietary main-
tenance than the low attendance group.
The increase in the intake of fat during 1 year is sur-
prising in light of the mechanisms of action of orlistat
which may lead to gastrointestinal problems if dietary
fat is not restricted. Gastrointestinal symptoms are
thought to occur with a dietary intake of fat >30% of
total energy [17], but individual tolerability may vary.
Thus, subjects may increase their intake of fatty dairy
products without experiencing gastrointestinal problems.
It has also been speculated that subjects treated with
orlistat learn to titrate their dietary intake of fatty foods
[11]. Another possibility is that some subjects did not
use the medication as prescribed.
We found that energy density increased during the year
of follow-up however, change in energy density was not
associated with weight loss. On the other hand, the high
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density during treatment with orlistat more successfully
than the low attendance group. A reduced energy density
has been associated with weight loss in two previous stu-
dies [18,19]. The PREMIER study showed improved
weight loss in subjects with the largest reduction in
energy density compared to the subjects with the lowest
reduction [18]. The study by Ello-Martin et al. showed
that subjects who reduced fat intake with a concomitant
increase in vegetables and fruit lost more in weight and
reported less hunger compared to subjects that only
reduced their fat intake [19] supporting the notion that
energy density is a determinant of weight loss.
We found that increased protein intake was associated
with improved weight loss, in line with previous data
[20-22]. Dietary protein is associated with increased energy
expenditure and less hunger [22]. We speculate that less
hunger may have particular importance for subjects with
SRBD since reduced sleep quality may interfere with appe-
tite [23].
Table 1 Dietary intake after 1 year of treatment with orlistat
All participants
(n = 63)
High attendance group
(n = 31)
Low attendance group
(n = 32)
P*
Energy intake (kJ)
1 year 9229 ± 2304† 8747 ± 2033 9696 ± 2483
Change‡ 178 [-366, 722] § -57 ± 1618 406 ± 2661 0.409
Energy density (kJ/g)
1 year 5.3 ± 1.5 4.7 ± 1.2 5.9 ± 1.5
Change 0.5 [0.2, 0.7] 0.1 ± 0.9 0.8 ± 1.0 0.008
Fat (E%)
1 year 29.7 ± 7.3 27.3 ± 6.5 32.0 ± 7.4
Change 1.7 [-0.2, 3.6] 0.2 ± 6.6 3.2 ± 8.5 0.117
Saturated fat (E%)
1 year 10.1 ± 3.7 8.6 ± 2.4 11.5 ± 4.1
Change 1.2 [0.4, 2.0] 0.7 ± 1.7 1.7 ± 4.2 0.201
Monounsaturated fat (E%)
1 year 10.1 ± 3.7 8.6 ± 2.4 11.5 ± 4.1
Change -1.3 [-2.2, -0.3] -2.6 ± 2.9 0 ± 4.5 0.009
Polyunsaturated fat (E%)
1 year 5.4 ± 1.7 5.3 ± 2.1 5.4 ± 1.3
Change 0 [-0.5, 0.5] -0.3 ± 2.2 0.3 ± 1.4 0.169
Protein (E%)
1 year 17.4 ± 2.7 18.3 ± 2.5 16.5 ± 2.6
Change 0 [-0.6, 0.8] 0.8 ± 3.3 0.3 ± 1.4 0.051
Carbohydrate (E%)
1 year 47.7 ± 6.5 48.7 ± 6.3 46.7 ± 6.5
Change -1.9 [-3.7, -0.2] -0.4 ± 5.9 -3.4 ± 1.4 0.089
Fiber (g/MJ)
1 year 3.9 ± 1.4 4.3 ± 1.5 3.5 ± 1.2
Change -0.3 [-0.6, -0.1] -0.1 ± 1.2 -0.5 ± 0.8 0.143
*Comparison of changes between the high and low attendance group (unpaired t-test). The subjects in the high attendance group attended more group
sessions than the mean which was 9.34 sessions and the subjects in the low attendance group attended = 9.34 sessions.
†Mean ± SD ‡Changes are calculated as the difference between 1 year and the start of orlistat. § Mean; 95% CI in brackets.
Table 2 Daily intake of food after 1 year of treatment
with orlistat in all participants (n = 63)
Food items Mean ±
SD
Change*
[95% CI]
P†
Vegetables, g 448 ± 235 -49 [-103, 5] 0.050
Fruit‡, g 424 ± 265 -42 [-120, 37] 0.122
Bread, g 162 ± 75 2 [-15, 19] 0.820
Potatoes, rice and pasta, g 155 ± 88 -4 [-28, 20] 0.421
Poultry and lean meat, g 110 ± 56 6 [-9, 20] 0.661
Fish, g 63 ± 51 -10 [-19, -1] 0.027
Fatty meat‡, g 46 ± 42 7 [-4, 18] 0.154
Sweets, cookies and desserts, g 43 ± 43 5 [-5, 15] 0.457
Butter, cream and fatty
cheeses, g
32 ± 36 11 [1, 21] 0.018
Oil‡, g 16 ± 11 -4 [-7, 0] 0.160
*Changes were calculated as the difference between intake at 1 year and start
of the treatment with orlistat. † Comparisons between the intake of food at
start of the treatment with orlistat and after 1 year (the Wilcoxon signed rank
test). ‡ Fatty meat includes minced meat, sausages, pork chops, salami; fruit
includes orange juice, berries and berry jam; oil includes original and fat
reduced soft margarine, mayonnaise and salad-dressings.
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with orlistat was about 5%. However, the subjects had
already lost about 3 kg of weight prior to the initiation of
orlistat. This total change is in accordance with the weight
reduction achieved in a sibutramine assisted weight loss
program in obese males with SRBD [24]. In this study,
favourable changes in the frequency of disordered breath-
ing events and cardio-metabolic risk factors were shown
concomitant with the loss in weight [24,25]. A limitation
of our study is that we did not measure the apnoea - hypo
apnoea index after weight reduction. However, most of
the participants used continuous positive airway pressure
for symptomatic treatment of their SRBD before weight
loss was initiated [12].
Conclusions
This study showed that treatment with orlistat for 1 year
in a group-based behavioural program was associated
with further weight reduction after an initial weight loss.
However, dietary energy density, and intakes of saturated
fat and fatty dairy products increased. Increasing dietary
protein and restricting fatty dairy products may improve
success with orlistat in obese subjects with SRBD.
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